56 Chapter 3 References 1. Cohen J, Vincent JL, Adhikari NK, Machado FR, Angus DC, Calandra T, et al. Sepsis: a roadmap for future research. The Lancet Infectious diseases. 2015;15(5):581-614. 2. Singer M. Biomarkers in sepsis. Current opinion in pulmonary medicine. 2013;19(3):305-9. 3. Perner A, Rhodes A, Venkatesh B, Angus DC, Martin-Loeches I, Preiser JC, et al. Sepsis: frontiers in supportive care, organisation and research. Intensive care medicine. 2017;43(4):496-508. 4. Bochud PY, Glauser MP, Calandra T. Antibiotics in sepsis. Intensive care medicine. 2001;27 Suppl 1:S33-48. 5. Bochud PY, Bonten M, Marchetti O, Calandra T. Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review. Critical care medicine. 2004;32(11 Suppl):S495-512. 6. Sims CR, Nguyen TC, Mayeux PR. Could Biomarkers Direct Therapy for the Septic Patient? The Journal of pharmacology and experimental therapeutics. 2016;357(2):228-39. 7. van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. Nature reviews Immunology. 2017. 8. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Critical care (London, England). 2010;14(1):R15. 9. Clinical Trials. List of open studies regarding “sepsis” AND “biomarkers” 2017 [Available from: https://www.clinicaltrials.gov/ct2/results?term=sepsis+AND+biomarkers&recr=Open. Accessed August 24, 2017. 10. Bloos F, Reinhart K. Rapid diagnosis of sepsis. Virulence. 2014;5(1):154-60. 11. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive care medicine. 2017;43(3):304-77. 12. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. The Lancet Infectious diseases. 2016;16(7):819-27. 13. Gibot S, Bene MC, Noel R, Massin F, Guy J, Cravoisy A, et al. Combination biomarkers to diagnose sepsis in the critically ill patient. American journal of respiratory and critical care medicine. 2012;186(1):65-71. 14. Casserly B, Read R, Levy MM. Multimarker panels in sepsis. Critical care clinics. 2011;27(2):391-405. 15. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Critical care (London, England). 2007;11(2):R38. 16. Klein Klouwenberg PM, Cremer OL, van Vught LA, Ong DS, Frencken JF, Schultz MJ, et al. Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study. Critical care (London, England). 2015;19:319. 17. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. The Journal of clinical endocrinology and metabolism. 1994;79(6):1605-8. 18. Brunkhorst FM, Heinz U, Forycki ZF. Kinetics of procalcitonin in iatrogenic sepsis. Intensive care medicine. 1998;24(8):888-9. 19. Meisner M, Lohs T, Huettemann E, Schmidt J, Hueller M, Reinhart K. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. European journal of anaesthesiology. 2001;18(2):79-87.
RkJQdWJsaXNoZXIy MTk4NDMw